Currently, the approved agents for treatment of CRC include monoclonal antibodies or small molecule tyrosine kinase inhibitors against the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways, as well as the standard chemotherapeutic agents 5-FU, irinotecan, and oxaliplatin (Ortega et al., 2010; Bagnasco et al., 2012; Strumberg et al., 2012). Here, VEGFA is linked to colorectal carcinoma.